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1. Introduction 
Long-term drainage of the urinary tracts of patients with impassable ureteric strictures 
remains a major challenge to the urologist. Until the mid 1970’s the only viable, minimally 
invasive treatment was a permanent nephrostomy with all its sequelae, loss of quality of life, 
risk of tube dislocation, infection, and recurrent obstruction (Marberger, 2006). For decades, 
researchers experimented with different prosthetic ureteric replacements with minimal 
success. with minimal success. The breakthrough came in 1976 with a case report of the first 
successful prosthetic replacement of both ureters in a patient with malignant obstruction. 
The authors proved that not only were prosthetic materials possible replacements for 
ureters, peristaltic activity was not needed for permanent normal function of the upper 
urinary tract (Schulman, et al., 1976). This landmark study resulted in rapid progress in the 
investigation for potential materials for ureteric replacement that could be used without 
need for major reconstructive surgery. However, it was not until 1994 that the first viable 7F 
double-pigtail prosthetic extra-anatomic bypass system was developed (Lingam et al., 1994). 
Despite several series reporting excellent outcomes during the last two decades, extra-
anatomic stenting is not yet universally offered to candidate patients. 
Conventionally, such patients are offered a minimally invasive procedure in the form of a 
percutaneous nephrostomy or alternatively reconstructive surgery. Percutaneous 
nephrostomy, though minimally invasive, is far from ideal for long-term use. Reconstructive 
surgery overcomes some of the problems related to long-term nephrostomy use; however, it 
requires patients to undergo major surgery. Unfortunately, the majority of impassable 
ureteric strictures are due to malignant disease, which has been reported to carry a poor 
prognosis with a resulting median survival of 3 to 7 months (Kouba et al., 2008). This 
prognosis highlights the importance of maintaining quality of life in this group of patients 
and major reconstructive surgery with all its potential sequelae, should ideally be avoided. 
An ideal urinary diversion should provide symptomatic relief for the required duration 
without requiring multiple changes and should be associated with minimal or no morbidity. 
Several authors have reported their experience of using extra-anatomical stents (EAS) for 
temporary or permanent drainage of obstructed urinary tracts (Ahmadzadeh, 1991; Lingam 
et al., 1994; Nakada et al., 1995; Desgrandchamps et al., 1998a 1998b; Minhas et al., 1999; 
Lloyd et al., 2007). In this chapter, we describe the indications for and the technique of 
inserting the EAS, and a review of the results from the major series.  
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2. Patient indications 
The main indication for insertion of an EAS is malignant ureteric obstruction that has failed 
management with internal ureteric stenting or nephrostomy (Fig 1a-b). Patients with benign 
ureteric obstruction that have either failed open reconstructive surgery or are unfit or 
unwilling to undergo open surgery can also be considered for EAS. Increasing experience 
with EAS has been paralleled by an expansion in it is indications. At our institution for 
example, we have successfully used EAS to treat intractable urinary incontinence due to 
ureteric fistulae in patients otherwise unfit for open surgical repair. In some patients, it has 
been used as a temporary measure for ureteric fistula before definitive repair is carried out. 
Lastly, EAS is increasingly being used in transplanted kidneys (Olsburgh , 2007) as well as 
in patients with ileal conduit (own series). 
 
Fig. 1a. Bilateral Extra-anatomic stents of the Paterson Forrester type (short-term). There is 
also trans-ureteric ureterostomy stent seen in-situ to be removed. Patient had bilateral 
strictures and fistula after reconstruction in a post-irradiated abdomen and several attempts 
at corrective surgery without success. 
The only absolute contraindications are uncorrected coagulopathies and active malignancy, 
either arising or invading the bladder. Tumour seeding along the track may occur if the 
stent is placed near a tumour (Fig. 2). Bowel stomas and multiple abdominal scars make 
stent placement more challenging but are not a contraindication. Likewise, patients with a 
small capacity bladder require appropriate counseling regarding potential increased urinary 
frequency especially if they have been managed with nephrostomy for a long time. Patients 
should be warned of the risk of subcutaneous infection that will usually respond to a course 
of appropriate antibiotic. Rarely, the infection may necessitate removal of the stent with a  
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Fig. 1b. Cystogram in a patient with a Detour extra-anatomic stent (permanent type) for 
ureteric obstruction after sarcoma excision. 
temporary conversion of the proximal end to a nephrostomy. Rarely still, stent blockage 
may occur requiring change before 12 months. In our experience, storage bladder symptoms 
from the stent are exceptionally rare and no stent was ever removed at our institution due to 
this problem.  
3. Stents  
Different types of EAS have been developed and used successfully by different authors 
(Lingam, 1994; Minhas, 1999; Desgrandchamps, 1998a;, Lloyd, 2007). The designs have 
varied with the materials used, length of stent, diameter of stent and on whether one or 
composite stent/s are utilized. They however, all have a common objective of establishing a  
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Fig. 2. Tumour invasion along the route of an extra-anatomic stent. 
nephro-vesical subcutaneous urinary diversion. The diameter of the stent is thought to be 
the main determinant of the duration the stent may remain in situ without encrustation or 
blocking. It has been estimated that a 17 F diameter is required to prevent stent encrustation 
irrespective of its composition in association with increased fluid intake (Andonian, et al. 
2005). 
To this end, we utilize two types of stents in our practice. One is a short-term 8.5F 65cm EAS 
without side holes except at either end. We offer to all patients with malignant disease and 
in patients with poor general health and benign disease where there is concern regarding 
the functionality of the bladder. If they survive the first change and have a good prognosis, 
we will usually discuss conversion to a more long-term 29F Detour EAS. The latter stent 
requires a more invasive technique including an open cystostomy but has the advantage of 
potentially being a permanent diversion with a single procedure. We use it as a primary 
option in patients with a long life expectancy. Below, we describe our technique of inserting 
both types of stents. 
4. The Paterson-Forrester stent 
4.1 Equipment 
The Paterson-Forrester 65cm, 8.5F polyurethane stent (Cook Ireland Ltd) 
Cystoscopy tray for either (flexible or rigid cystoscopy) 
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Percutaneous nephrostomy track placement tray with telescopic metal dilators to size 3 (18F).  
Contrast solution in a luer lock syringe 
Minor operation tray with scalpel, tissue forceps and clips 
Dissecting scissors  
Needle holder and absorbable sutures 
Nephrostomy needle and 0.38F j tip wire 
12 F peel away sheath 
0.38F floppy tip stiff core Sensor wire (Microvasive) 
Extra equipment for exchange of stent 
6F end flushing ureteric catheter  
Flexible rat-toothed stent removing forceps if flexible cystoscope is used  
4.2 First time insertion PF stent 
The procedure for insertion involves three steps: 
1. Insertion of stent in the kidney via a new or existing nephrostomy tract. Our preferred 
option is to use the track of an existing nephrostomy tube after a minimum of 5 days 
insertion. 
2. Creation of a subcutaneous tunnel and tunneling of the stent to reach the supra-pubic 
region.  
3. Creation of a supra-pubic tube cystostomy and insertion into the bladder in the bladder. 
Step 1 
For unilateral placement, the patient is positioned in the Lloyd-Davis position, with the ipsi-
lateral leg in extension and the affected side elevated to approximately 200 with 3 litre saline 
bags. Gram-negative antibiotic prophylaxis is given – usually Gentamicin 2mg/Kg. The skin 
is prepared with aqueous iodine and draping applied to leave the abdomen and 
nephrostomy tube exposed (Fig. 3). The C-arm is positioned at the opposite side of the stent 
insertion while the camera with stack is placed near the foot of the table opposite the 
operator. An assistant needs to be able to perform a cystoscopy at the same time the 
operator places the upper end of the stent as detailed below. 
Ideally the patient already has a nephrostomy tube in place and thus the following steps are 
undertaken. However, it is possible to create a new track and deliver the proximal end of the 
stent into the kidney de-novo. Local anaesthetic is injected into the skin around the 
nephrostomy tube and contrast is injected to opacify the collecting system. A 0.38F Sensor 
guide wire (Microvasive) is passed through the existing nephrostomy tube and the tube 
removed under screening leaving the wire in the system. The tapered end of the EAS is 
placed into the collecting system over the wire producing a good coil in the kidney. The skin 
incision is extended in a transverse direction for 2cm and the existing cutaneous aspect of 
the existing fistulous track is excised and dissected free from the rest of the tract in order to 
allow the stent to sit below the skin cutaneous margin (Fig. 4). 
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Fig. 3. Patient positioning over the edge of the operating table with fluid bags elevating the 
side and the nephrostomy tube included in skin preparation. 
 
Fig. 4. The Paterson-Forrester extra-anatomic stent is passed over a guide wire and replaces 
the nephrostomy tube. The skin bridge is dissected free. 
Step 2 
The Alken PCNL coaxial metal dilators are used to create a multi-stage subcutaneous tunnel 
(Fig. 5). The 9F long metal guide rod is passed in the subcutaneous fat layer obliquely 
towards the iliac fossa. The tract is sequentially dilated to 18F. After injection with local 
anaesthetic the skin is incised over the tip of the dilators at a point that allows control of 
both ends of the dilators. The smaller dilators are retrieved from the new incision leaving 
only the 18F dilator in place through which the EAS is passed towards the bladder. The 
metal dilator is then retrieved distally leaving the stent in a new subcutaneous tunnel. The 
procedure is repeated two or three times depending upon the route taken to the supra-pubic 
area avoiding scars and or stomas.  
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Fig. 5. The Alken dilators used to create a subcutaneous tunnel down to the supra-pubic 
region. 
Step 3 
The site of the last skin incision should be in the supra-pubic region but lateral to the 
midline. An assistant performs a cystoscopy to allow visualization of the stent as it is 
inserted into the bladder using a modified Seldinger technique with the aid of a 12 F peel-
away sheath. Before the stent is finally delivered into its final subcutaneous tunnel the 
position of proximal end of the stent is checked with x ray screening (Fig. 6). The presence of 
a cystoscope should prevent distal stent migration out through the urethra. The skin is 
closed with absorbable sutures and skin glue. 
4.3 Exchange of PF stent 
Stents are changed routinely at 12 months (although licensed for 3 months), using the 
following technique:  
A clip is used to identify a suitable position to incise the skin anteriorly, ideally half way 
along the stent but any position proximal to the bladder is acceptable. It is better to be able 
to see this site and the proximal coil in the kidney in the same fluoroscopic image. Making a 
small transverse incision at the appropriate site exposes the stent. The stent is then cut and a 
Sensor guide-wire passed through the proximal portion of the stent, which is then removed. 
The new stent is passed over the guide-wire before withdrawing the wire. The guide-wire is 
then passed into the bladder via the distal end of the old stent, which is then removed. The 
distal end of the new stent is passed over the wire into the bladder and the guide-wire 
removed endoscopically from the distal end of the stent (Minhas et al., 1999). 
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Fig. 6. Supra-pubic puncture and peel-away sheath used to deliver stent into the bladder 
under cystoscopic control.  
 
Fig. 7. Wounds closed with subcutaneous absorbable sutures and skin glue. 
5. Insertion of the detour stent 
The equipment required are provided as a kit and include the 29F PTFE-silicone stent and 
the dilator (Coloplast, UK). In addition, a surgical set suitable for a lower abdominal 
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transverse incision is required. Insertion of the permanent Detour stent follows the same 
principals described above but because it is a bigger stent (29F), it requires the tract to be 
dilated to 30F (Lloyd et al., 2007). This is achieved with a 30F renal Amplatz sheath and a 
large-bore plastic subcutaneous tunneling device, which are included in the kit (Fig. 8a-f). A 
lower abdominal transverse incision is undertaken before a 1cm open cystostomy is 
performed via which the stent is placed into the bladder and secured with 4-0 Vicryl sutures 
to the bladder serosa. The large bore subcutaneous stent can be easily palpated and seen in 
the thin patient (Fig. 9). 
 
Fig. 8a. Lateral percutaneous track using the existing nephrostomy to inject contrast to 
outline and dilate the pelvi-calyceal system 
 
Fig. 8b. Insertion of the proximal end of the Detour stent through the Amplatz sheath into 
the kidney (note yellow radiolucent ring to aid positioning).  
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Fig. 8c. Opaque contrast medium injected through the stent to ensure correct positioning. 
 
Fig. 8d. Subcutaneous tunneling device (blue) and Detour stent being positioned from renal 
puncture site to supra-pubic region prior to bladder suture 
 
Fig. 8e,f. Sutured cystostomy after shortening the stent,  skin glue is applied to wounds  
after subcutaneouse sutures and glue. 
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Fig. 9. Wide bore Detour stent may be palpable in thin patients. Healed incisions are visible.  
6. Post-operative management and follow-up 
A Foley catheter may be left in the bladder for a few hours to observe fluid balance but it is 
not essential following insertion of the short term EAS. Patients are usually discharged 
home on the day of surgery or the following day. The referring physician monitors the renal 
function. The patients are instructed to seek medical help immediately if they develop any 
signs of local or systemic sepsis. Following placement of the Detour stent, an indwelling 
catheter is left in situ for 1 week, and a cystogram is performed to check the integrity of the 
suture line before catheter removal (Fig. 10). Flexible cystoscopic view may show some 
mucosal oedema at the site of implantation (Fig. 11). 
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Fig. 10. Cystogram used to check for suture line integrity. 
 
Fig. 11. Cystoscopic appearance of the silicone part of the Detour stent. 
7. Discussion of results 
End-stage ureteric obstruction, which has failed ureteric stenting, presents a significant 
challenge the urologist. Most of our patients have terminal cancer and are therefore not ideal 
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candidates for major reconstructive surgery. The remainder of the patients have either failed 
or declined reconstructive surgery, or are too frail for major surgery. The conventional 
practice of managing this group of patients is with external percutaneous nephrostomy 
drainage. Unfortunately long-term nephrostomy drainage presents significant compromises 
to the patient's quality of life in addition to requiring regular changes.  
In 1991, Ahmadzadeh reported short-term results in 8 patients with ureteric obstruction 
who underwent subcutaneous urinary diversion using a specially designed stent. The 
procedure had the advantage of being simple whilst at the same time avoided the 
complications and social effects of other methods of palliative treatment by urinary 
diversion (Ahmadzadeh 1991). Since this pioneering article, several authors have reported 
their experience with different types of EAS for urinary diversion. In 1994 Lingam and 
colleagues reported their series of 5 patients who had EASs inserted during a 15-month 
period. The diversion was created using a specially designed 7F double pigtail stent, which 
they routinely changed at 4-month intervals. They found it to be a safe, effective and an 
acceptable alternative to nephrostomy drainage that improved quality of life (Lingam et al., 
1994). A year later, another small study reported a marked improvement in patients’ overall 
comfort and quality of life following conversion of nephrostomies to EASs using a similar 
but slightly larger 8.5F stent (Nakada et al., 1995). In the same year, Desgrandchamps 
introduced another stent prototype, which was a one-piece, self-retaining expanded 
polytetrafluoroethylene-silicone tube that was successfully assembled as an EAS in 19 
patients with a mean follow-up of 7.2 months. All patients expressed an improvement in the 
quality of life although in one case, a conversion to a conventional percutaneous 
nephrostomy was necessary (Desgrandchamps et al., 1995).  
In 1999, our group published results of 13 patients treated with EAS. Urinary diversion was 
successful in all patients; two survived for more than 1 year, with changes at six monthly 
intervals. In three patients the stents were replaced by percutaneous nephrostomies because 
of problems with leakage or infection. The remaining patients died with functioning EAS in 
situ. For the first time long-term follow up was reported. This study showed that the mean 
(range) time from stent placement to death was 7.5 (3–18) months. It was also the first time 
in the literature that an EAS had been used in a patient with a benign stricture of a native 
ureter. The patient remained well and was alive to the end of the study at 24 months 
(Minhas et al., 1999). Since this original publication, we have implanted over one hundred 
EAS in candidate patients at our institution with equally excellent results (unpublished 
series). 
One drawback of this one-piece stent was its long length of 70-cm, which some found to be 
complex to implant, time-consuming, and cumbersome for the patient (Schmidbauer et al., 
2006). Nissenkorn and Gdor developed a two 14F 50-cm polyurethane J stents joined by a 
connector. After stent placement was confirmed by injecting a contrast agent through the tube, 
the stents were intra-operatively shortened as needed before linking them together. They used 
the stents successfully in eight patients with a mean follow up of mean 5.5 months 
(Nissenkorn & Gdor, 2000). In 2006, Schmidbauer et al. reported their successful results using 
a composite prosthesis set composed of two 12F polyurethane J-tubes, a 58-cm percutaneous 
nephrostomy part and a 56-cm percutaneous cystostomy part, malleable tunnelers, and a 
metal connector for joining the two tubes. In 27 patients followed up for 12 months (2 – 54 
months) an improvement in mean quality of life score from 3.4+/-1.4 pre-operatively to 7.6+/-
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1.0 post-operatively was reported. In five patients (17.9%) the system had to be replaced due to 
occlusion at a mean follow-up of 10.2 months. In three out of these five patients only the distal 
part of the two-piece bypass was exchanged (Schmidbauer et al., 2006). 
Desgrandchamps et al. were the first authors to report use of a permanent PTFE-silicone 
EAS (Detour). They reported 3 patients who underwent successful EAS for ureteric necrosis, 
a rare complication of renal transplantation (Desgrandchamps et al., 1998). In 2001, the same 
group, reported use of the PTFE-silicone EAS in 27 patients with neoplastic (22) or benign 
(5) ureteric strictures. The mean follow-up was 6.3 months for the deceased patients and 47 
months for the surviving ones, the longest follow-up being 84 months. In 3 cases, the EAS 
had to be removed due skin erosion in one and local tumour progression with bladder 
fistulae in two patients. Otherwise, five patients survived with the prosthesis in situ and a 
follow-up as long as 84 months without encrustation, infection, obstruction, or skin 
problems and with normally functioning kidneys (Jabbour et al., 2001). A prospective 
evaluation of their patients’ quality using the EORTC QLC-30 questionnaire following 
insertion of the Detour EAS demonstrated an improvement of the function scale as a result 
of the elimination of the external percutaneous tube and a parallel worsening of the 
symptom scale secondary to the progression of disease (http://groups.eortc.be/qol/ 
questionnaires_qlqc30.htm). Patient ratings of the global quality of life and satisfaction with 
the urinary diversion were high because of the absence of the percutaneous tube 
(Desgrandchamps et al., 2007). Other authors have since reported equally excellent results 
with the Detour EAS (Lloyd et al., 2007; Olsburgh et al., 2007; Burgos et al., 2009).  
Aminsharifi A et al. recently described a promising simple modification of using 
percutaneous access to the bladder utilizing a split Amplatz sheath, and thus obviating the 
need for open cystostomy incision (Aminsharifi et al., 2010). 
The main long-term complication reported is tumour invasion along the stent and active 
bladder cancer is the main contraindication to EAS insertion. One case report reported a 
patient presenting with acute obstruction of the Detour system secondary to a Candida 
infection that was managed successfully with short term nephrostomy and systemic anti-
mycotic therapy without removing the stent (Bynens et al., 2006).  
8. Conclusion 
The long term data show that EAS offers an excellent temporary or permanent 
internalization of urinary drainage with a minimally invasive method where open surgery 
has been tried and failed or was not considered feasible, and avoids the need for long-term 
nephrostomy drainage.  
An ideal EAS should be associated with minimal or no peri-operative morbidity; whilst at 
the same time does not require regular changes. Such a stent does not currently exist but it is 
likely that the rapid advancement in tissue engineering and biomaterials will make it 
possible to design one soon. 
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